Recall depth, public warnings and effectiveness checks, the three parts of a recall strategy

From January 2024 through Oct. 28, 2026, FDA classified 193 drug recall product records as Class I, its most serious category. In 86 of them, about 45 percent, the recalling company's first notice went out as a press release, according to GxRadar's analysis of openFDA enforcement data¹³. Among 1,749 Class II records over the same period, 34 began that way, under 2 percent. Among 183 Class III records, none did.

Those splits are the visible trace of a recall strategy, the plan every recall is supposed to follow. Federal rules at 21 CFR 7.42¹ say a strategy will address three things: how far down the distribution chain the recall reaches, whether the public needs a warning, and how thoroughly the company checks that customers got the message and acted on it.

Those rules date from 1978 and are mostly framed as guidance. FDA filled in the detail with a 2019 guidance on public warnings, a 2022 guidance on starting voluntary recalls and its internal Regulatory Procedures Manual⁹. This piece explains each element, including the five effectiveness check levels labeled A through E, and what the enforcement data show about how they are used.

What goes into a strategy

Section 7.42(a) lists five factors a strategy should weigh: the results of FDA's health hazard evaluation, how easily the product can be identified, how obvious the defect is to the person using it, how much of the product remains unused on the market, and the "continued availability of essential products." That last factor is the one that ties recalls to FDA's shortage list. Pulling every lot of a drug with few makers can create a shortage of its own.

For a firm-initiated recall, the company drafts the strategy and FDA reviews it and recommends changes. The regulation says the firm "need not delay initiation of a recall pending review." FDA's 2022 guidance⁷ adds that the strategy should anticipate the recall growing "should additional lots or products be shown to be affected," and that FDA treats the date of the firm's first communication to customers or the public as the recall's start date.

Depth of recall

Depth means the lowest level of the supply chain the recall must reach. Section 7.42(b)(1) sets three levels: the consumer or user level, which includes any wholesale or retail level in between; the retail level, which includes wholesale; and the wholesale level alone. Pharmacies, hospitals and clinics are all retail or user-level consignees, a term 21 CFR 7.3(n)² defines as "anyone who received, purchased, or used the product being recalled."

Class and depth usually line up but are not locked together. The procedures manual says that "in general," Class I recalls may extend to consumers, Class II to retail and Class III to wholesale, while noting that strategies "are not necessarily dependent on the recall classification." FDA's consumer page¹¹ uses the same rule of thumb.

Reaching a given depth depends on paperwork that exists before anything goes wrong. FDA's CGMP rules require drug distribution records⁶ showing each consignee's name and address, the date and quantity shipped, and the lot number, and section 7.59⁵ advises firms to keep such records longer than a product's shelf life. Lot coding is the other half, which is why lot numbers on packages and the product identifiers required for many prescription drugs matter in a recall.

Even the notice has a prescribed look. Under section 7.49³, a recall letter and envelope should be marked "DRUG RECALL," preferably in bold red type, and "URGENT" for Class I and II recalls. The letter should name the product, size and lot numbers, explain the reason and the hazard, say what to do with the product and give the recipient an easy way to report back. Each customer that received the notice should pass it on to its own customers when the strategy calls for that.

Public warnings

A public warning, in the regulation's words, exists "to alert the public that a product being recalled presents a serious hazard to health," and it is "reserved for urgent situations where other means for preventing use of the recalled product appear inadequate." It can go out through general news media or through specialized channels such as professional journals or notices to hospitals and physicians.

FDA's 2019 guidance⁸ says the agency has generally issued or sought a public warning in Class I or potential Class I recalls unless there is a specific reason not to, and also recommends them for some urgent Class II recalls. Its list of examples includes "sterile injectable drug products which may contain particulate matter," and it says a warning may be needed for prescription drugs when retail-level customers such as pharmacies "cannot identify persons to whom the drug" was dispensed. Once FDA tells a firm a warning is appropriate, the guidance says the firm should generally issue it within 24 hours.

Source: GxRadar analysis of the "initial firm notification" field in openFDA drug enforcement records by report date. Records marked "two or more" methods, telephone, other or blank are not shown, so rows do not sum to 100 percent. The field records the first method only, so a recall that began by letter can still get a press release later.

Over the full record, back to June 2012, 943 of 1,753 Class I records began with a press release, or 54 percent. The enforcement report's field definitions¹² describe the column as the method "by which the firm initially notified the public or their consignees."

Effectiveness checks, levels A to E

An effectiveness check verifies that every consignee at the chosen depth received the notice "and have taken appropriate action," in the words of section 7.42(b)(3). The recalling firm ordinarily runs the checks by personal visits, phone calls, letters or a mix. The strategy has to name both the method and the level.

An attachment to the procedures manual lays out the mechanics, under the same title as a guide the regulation still says is "available upon request" from FDA's dockets office. Each consignee gets a number, every response is logged against it, and the questionnaire asks whether the notice arrived, whether the product was handled as instructed, and whether it had already been shipped onward before the notice came. FDA posts model effectiveness check letters and questionnaires¹⁰ for drug recalls on its industry page.

FDA runs its own spot checks too. The manual calls them recall audit checks, says the division monitoring a recall will consider assigning them for potential Class I and II recalls, and notes they "are not normally performed for Class III recalls." The agency can use state partners or contractors, and can step in directly when a firm cannot check, for example when customers paid cash and left no record. Levels can differ by tier of the supply chain. A sample entry in the manual reads "Recommend level C (10%) audit checks at distributor accounts and level D (2%) not to exceed five sub accounts of each distributor audited."

Status reports and the end of a recall

While a recall runs, section 7.53⁴ asks the firm for status reports, generally every two to four weeks. Each should give the number of consignees notified and how, how many responded, how many did not, how much product came back, and the "number and results of effectiveness checks that were made."

If the checks show the recall is not working, section 7.40(c) says seizure or other court action is indicated when FDA "determines that a recall is ineffective." When FDA concludes that all reasonable efforts have been made, it terminates the recall under section 7.55, and our explainer on how recalls end covers that step.

Many recalls stay open for a long time. Of the 657 drug recall product records FDA reported in 2024, 360 were still listed as ongoing as of Oct. 28, 2026, against 258 terminated and 39 completed, according to openFDA. Year-by-year counts sit on the GxRadar recall tracker, and our guide to recall terms explains what never reaches the list.